| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13724 | 2012 |
| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9464 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6002 | 2017 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167, 2010 | 3548 | 2010 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020, 2014 | 2662 | 2014 |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical cancer research 20 (19), 5064-5074, 2014 | 2515 | 2014 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy SL Topalian, JM Taube, RA Anders, DM Pardoll Nature Reviews Cancer 16 (5), 275-287, 2016 | 2513 | 2016 |
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ... Science translational medicine 4 (127), 127ra37-127ra37, 2012 | 2401 | 2012 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 1983 | 2016 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 1901 | 2018 |
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints NJ Llosa, M Cruise, A Tam, EC Wicks, EM Hechenbleikner, JM Taube, ... Cancer discovery 5 (1), 43-51, 2015 | 1472 | 2015 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1272 | 2016 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1160 | 2022 |
| Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma S Lyford-Pike, S Peng, GD Young, JM Taube, WH Westra, B Akpeng, ... Cancer research 73 (6), 1733-1741, 2013 | 841 | 2013 |
| A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ... JAMA oncology 3 (8), 1051-1058, 2017 | 752 | 2017 |
| Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer KJ Lastwika, W Wilson III, QK Li, J Norris, H Xu, SR Ghazarian, ... Cancer research 76 (2), 227-238, 2016 | 716 | 2016 |
| Neoadjuvant checkpoint blockade for cancer immunotherapy SL Topalian, JM Taube, DM Pardoll Science 367 (6477), eaax0182, 2020 | 662 | 2020 |
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ... Clinical Cancer Research 19 (2), 462-468, 2013 | 660 | 2013 |
| Pd-1/pd-l1 inhibitors J Sunshine, JM Taube Current opinion in pharmacology 23, 32-38, 2015 | 618 | 2015 |
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment J Taube, D Halsall, T Baglin Blood, The Journal of the American Society of Hematology 96 (5), 1816-1819, 2000 | 561 | 2000 |
